Novel inhibitor of protein farnesyltransferase (FT), inhibiting the growth of P. falciparum in red blood cells and suppressing parasitemia

Novel Anabolic Selective Androgen Receptor Modulator (SARM)

Novel highly potent and selective inhibitor (type 1.5 binding mode) of MAPK14 [IC50 = 0.2 nM (ELISA, cell free); KD = 1.5 nM (DiscoverX)]

Novel N-Methyl-d-aspartate receptor (NMDAR) positive allosteric modulator (PAM) with potential antidepressant effects

Potent ligand for a protein site governed largely by van der Waals interactions, producing excitatory activity in tadpoles and mice; also antagonizing propofol-induced hypnosis

Novel Potent and Selective Covalent Inhibitor of KRAS G12C

Potent, selective, and orally active antagonist for central adenosine A1 receptors

Novel Nonpeptide Bradykinin B2-Receptor Partial Agonist

Potent and nonadrenotoxic ACAT inhibitor

Nonprostanoid PGI2 agonist

Natural specific inhibitor of mammalian NSDHL and yeast Erg26p, inhibiting an artificial Hepatitis C viral replicon, and showung broad antifungal activity

Selective ET(A) receptor antagonist

Novel agonist of the formyl peptide receptor (FPR), protecting against myocardial ischaemia-reperfusion injury in mice

Novel NO-donating antimicrobial peptide, exhibiting Staphylococcus aureus and Escherichia coli biofilm dispersion and eradication, and potent antibacterial activities in vitro

Novel Photochromic Ion Channel Blocker

Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor

Novel dipeptidyl peptidase IV (DPP4) inhibitor

Natural antibiotic, acting as an inhibitor of DOXP reductoisomerase

Impurity of Lenalidomide

Local anaesthetic agent, blocking voltage-gated Na(+) currents in neurons

Novel ALK PROTAC, being capable of degrading ALK in a folate receptor-dependent manner in cancer cells

Novel BRD PROTAC, being capable of degrading BRDs in a folate receptor-dependent manner in cancer cells

Inhibitor of IspD and IspE enzymes isolated from bacteria

Novel fluorescent near-infrared (NIR) linker for building brighter labeled biomolecules, exhibiting no evidence of H-aggregation even at high labeling density when appended to monoclonal antibodies or virus-like particles

First in class anti-tubercular agent against sensitive and drug-resistant Mycobacterium tuberculosis (Mtb)

Novel AMPK activator, inhibiting growth and induces apoptosis in colon cancer and increasing apoptosis in triple negative and estrogen-receptor positive breast cancers

Novel concentration-dependent inhibitor of CRF1R-pPL cotranslational translocation at the level of the Sec61 complex

Novel potent dual CDK14 and CDK16 inhibitor

Novel potent and selective Dual inhibitor of PI3K-δ and PI3K-γ

Novel highly selective inhibitor of Aurora kinases A, B and C, with potent cellular activity and minimal off-target activity (PLK4)